Verrica Finally Gets Molluscum Treatment To The Finish Line

A long regulatory path finally ended in success for Verrica Pharmaceuticals, Inc., which obtained US Food and Drug Administration approval for Ycanth (VP-102), the first drug cleared for the dermatological condition molluscum contagiosum. But the company’s 24 July announcement of a financing to bridge the early years of product launch did not sit well with investors.

The approval, late on 21 July, followed three FDA complete response letters since the West Chester, PA-based company first filed Ycanth for approval in 2019. (Also see "Verrica’s Molluscum Product Set Back By FDA Usage Questions" - Scrip, 14 July, 2020.) The first CRL requested additional chemistry, manufacturing and controls data from Verrica, while the second and third letters pertained to issues not related specifically to the drug at a third-party manufacturer